Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

Changes to clinician attire have done more harm than good.

Dancer SG, Duerden BI.

J R Coll Physicians Edinb. 2014;44(4):293-8. doi: 10.4997/JRCPE.2014.410.

PMID:
25516900
2.

In memoriam--Professor J Gerald (Gerry) Collee CBE, FRSE, MD, FRCPath, FRCPE (1929-2013).

Duerden BI, Watt B, Poxton IR.

J Med Microbiol. 2014 Apr;63(Pt 4):623-4. doi: 10.1099/jmm.0.070508-0. Epub 2014 Feb 3. No abstract available.

PMID:
24493158
3.

MRSA: why have we got it and can we do anything about it?

Duerden BI.

Eye (Lond). 2012 Feb;26(2):218-21. doi: 10.1038/eye.2011.314. Epub 2011 Dec 2.

4.

Contribution of a government target to controlling Clostridium difficile in the NHS in England.

Duerden BI.

Anaerobe. 2011 Aug;17(4):175-9. doi: 10.1016/j.anaerobe.2010.12.004. Epub 2010 Dec 21.

PMID:
21182972
5.

Analysis of prevalence, risk factors and molecular epidemiology of Clostridium difficile infection in Kuwait over a 3-year period.

Jamal W, Rotimi VO, Brazier J, Duerden BI.

Anaerobe. 2010 Dec;16(6):560-5. doi: 10.1016/j.anaerobe.2010.09.003. Epub 2010 Sep 29.

PMID:
20887795
6.

Correlation of multidrug resistance, toxinotypes and PCR ribotypes in Clostridium difficile isolates from Kuwait.

Jamal WY, Rotimi VO, Grubesic A, Rupnik M, Brazier JS, Duerden BI.

J Chemother. 2009 Nov;21(5):521-6.

PMID:
19933043
7.

Responsibility for managing healthcare-associated infections: where does the buck stop?

Duerden BI.

J Hosp Infect. 2009 Dec;73(4):414-7. doi: 10.1016/j.jhin.2009.06.027. Epub 2009 Sep 17. Review.

PMID:
19765862
8.

Distribution and antimicrobial susceptibility patterns of Clostridium difficile PCR ribotypes in English hospitals, 2007-08.

Brazier JS, Raybould R, Patel B, Duckworth G, Pearson A, Charlett A, Duerden BI; HPA Regional Microbiology Network.

Euro Surveill. 2008 Oct 9;13(41). pii: 19000.

9.

Infection control measures to limit the spread of Clostridium difficile.

Vonberg RP, Kuijper EJ, Wilcox MH, Barbut F, Tüll P, Gastmeier P; European C difficile-Infection Control Group; European Centre for Disease Prevention and Control (ECDC), van den Broek PJ, Colville A, Coignard B, Daha T, Debast S, Duerden BI, van den Hof S, van der Kooi T, Maarleveld HJ, Nagy E, Notermans DW, O'Driscoll J, Patel B, Stone S, Wiuff C.

Clin Microbiol Infect. 2008 May;14 Suppl 5:2-20. doi: 10.1111/j.1469-0691.2008.01992.x. Review.

10.

Confronting infection in the English National Health Service.

Duerden BI.

J Hosp Infect. 2007 Jun;65 Suppl 2:23-6. Review. No abstract available.

PMID:
17540236
11.

MRSA in non-clinical areas of hospitals.

Brown NM, Lee SD, Duerden BI, Gillanders SA, Cookson B, Neville L, Jenks P, Catchpole C, Wright P, Spencer RC.

J Hosp Infect. 2006 Dec;64(4):402-3. Epub 2006 Sep 18. No abstract available.

PMID:
16984805
12.
13.

Health protection: microbiology and the public health response to the bioterrorism threat.

Duerden BI.

Anaerobe. 2006 Apr;12(2):59-62. Epub 2005 Nov 14. Review. No abstract available.

PMID:
16701614
14.

Molecular investigation of genetic elements contributing to metronidazole resistance in Bacteroides strains.

Sóki J, Gal M, Brazier JS, Rotimi VO, Urbán E, Nagy E, Duerden BI.

J Antimicrob Chemother. 2006 Feb;57(2):212-20. Epub 2005 Dec 7.

PMID:
16338949
15.

Soft tissue infections caused by spore-forming bacteria in injecting drug users in the United Kingdom.

Brett MM, Hood J, Brazier JS, Duerden BI, Hahné SJ.

Epidemiol Infect. 2005 Aug;133(4):575-82. Review.

16.

Actinomyces dentalis sp. nov., from a human dental abscess.

Hall V, Collins MD, Lawson PA, Falsen E, Duerden BI.

Int J Syst Evol Microbiol. 2005 Jan;55(Pt 1):427-31.

PMID:
15653913
17.

Molecular characterization of nitroimidazole resistance in metronidazole-resistant bacteroides species isolated from hospital patients in Kuwait.

Jamal WY, Rotimi VO, Brazier JS, Johny M, Wetieh WM, Duerden BI.

Med Princ Pract. 2004 May-Jun;13(3):147-52.

18.

Actinomyces oricola sp. nov., from a human dental abscess.

Hall V, Collins MD, Hutson RA, Inganäs E, Falsen E, Duerden BI.

Int J Syst Evol Microbiol. 2003 Sep;53(Pt 5):1515-8.

PMID:
13130041
19.

Actinomyces nasicola sp. nov., isolated from a human nose.

Hall V, Collins MD, Lawson PA, Falsen E, Duerden BI.

Int J Syst Evol Microbiol. 2003 Sep;53(Pt 5):1445-8.

PMID:
13130031
20.

Corynebacterium atypicum sp. nov., from a human clinical source, does not contain corynomycolic acids.

Hall V, Collins MD, Hutson RA, Lawson PA, Falsen E, Duerden BI.

Int J Syst Evol Microbiol. 2003 Jul;53(Pt 4):1065-8.

PMID:
12892127
21.

Prevalent PCR ribotypes of clinical and environmental strains of Clostridium difficile isolated from intensive-therapy unit patients in Kuwait.

Rotimi VO, Jamal WY, Mokaddas EM, Brazier JS, Johny M, Duerden BI.

J Med Microbiol. 2003 Aug;52(Pt 8):705-9.

PMID:
12867566
22.

Antibiotic susceptibilities of Gram-positive anaerobic cocci: results of a sentinel study in England and Wales.

Brazier JS, Hall V, Morris TE, Gal M, Duerden BI.

J Antimicrob Chemother. 2003 Aug;52(2):224-8. Epub 2003 Jul 1.

PMID:
12837734
23.

Actinobaculum urinale sp. nov., from human urine.

Hall V, Collins MD, Hutson RA, Falsen E, Inganäs E, Duerden BI.

Int J Syst Evol Microbiol. 2003 May;53(Pt 3):679-82.

PMID:
12807186
24.

Actinomyces vaccimaxillae sp. nov., from the jaw of a cow.

Hall V, Collins MD, Hutson R, Inganäs E, Falsen E, Duerden BI.

Int J Syst Evol Microbiol. 2003 Mar;53(Pt 2):603-6.

PMID:
12710633
25.

Isolation and identification of Clostridium spp. from infections associated with the injection of drugs: experiences of a microbiological investigation team.

Brazier JS, Duerden BI, Hall V, Salmon JE, Hood J, Brett MM, McLauchlin J, George RC.

J Med Microbiol. 2002 Nov;51(11):985-9.

PMID:
12448683
26.

An outbreak of serious illness and death among injecting drug users in England during 2000.

Jones JA, Salmon JE, Djuretic T, Nichols G, George RC, Gill ON, Brazier JS, Brett MM, Duerden BI, Fry NK, Hall V, Hope V, Lieftucht A, McLauchlin J, Pitcher DG, Weild A.

J Med Microbiol. 2002 Nov;51(11):978-84.

PMID:
12448682
27.

Actinomyces cardiffensis sp. nov. from human clinical sources.

Hall V, Collins MD, Hutson R, Falsen E, Duerden BI.

J Clin Microbiol. 2002 Sep;40(9):3427-31.

28.

Fusobacterium necrophorum infections in England and Wales 1990-2000.

Brazier JS, Hall V, Yusuf E, Duerden BI.

J Med Microbiol. 2002 Mar;51(3):269-72.

PMID:
11871622
29.

PCR ribotyping of clinically important Clostridium difficile strains from Hungary.

Urbán E, Brazier JS, Sóki J, Nagy E, Duerden BI.

J Med Microbiol. 2001 Dec;50(12):1082-6.

PMID:
11761193
30.

Identification of clinical isolates of actinomyces species by amplified 16S ribosomal DNA restriction analysis.

Hall V, Talbot PR, Stubbs SL, Duerden BI.

J Clin Microbiol. 2001 Oct;39(10):3555-62.

31.

Wound microbiology and associated approaches to wound management.

Bowler PG, Duerden BI, Armstrong DG.

Clin Microbiol Rev. 2001 Apr;14(2):244-69. Review.

32.

Comparison of toxinotyping and PCR ribotyping of Clostridium difficile strains and description of novel toxinotypes.

Rupnik M, Brazier JS, Duerden BI, Grabnar M, Stubbs SL.

Microbiology. 2001 Feb;147(Pt 2):439-47.

PMID:
11158361
33.

Infections in AIDS.

Hart CA, Beeching NJ, Duerden BI, Curry A, French N, Kariuki S, Graham SM, Gordon MA, Hoggard PG, Kewn S, Back DJ.

J Med Microbiol. 2000 Nov;49(11):947-67. Review. No abstract available.

PMID:
11073149
34.

Letters to the Editor.

Brazier JS, Stubbs SL, Duerden BI.

J Hosp Infect. 2000 Aug;45(4):332. No abstract available.

PMID:
10973755
35.
36.
37.

Metronidazole resistance among clinical isolates belonging to the Bacteroides fragilis group: time to be concerned?

Brazier JS, Stubbs SL, Duerden BI.

J Antimicrob Chemother. 1999 Oct;44(4):580-1. No abstract available.

PMID:
10588328
38.

Prevalence of toxin A negative/B positive Clostridium difficile strains.

Brazier JS, Stubbs SL, Duerden BI.

J Hosp Infect. 1999 Jul;42(3):248-9. No abstract available.

PMID:
10440000
39.

Commentary: a matter of good clinical practice.

Weinberg R, Duerden BI.

BMJ. 1999 Jun 12;318(7198):1617-8. No abstract available.

PMID:
10428554
42.

PCR-ribotyping and pyrolysis mass spectrometry fingerprinting of environmental and hospital isolates of Clostridium difficile.

Al-Saif NM, O'Neill GL, Magee JT, Brazier JS, Duerden BI.

J Med Microbiol. 1998 Feb;47(2):117-21.

PMID:
9879953
43.

Guidelines for optimal surveillance of Clostridium difficile infection in hospitals.

Brazier JS, Duerden BI.

Commun Dis Public Health. 1998 Dec;1(4):229-30.

PMID:
9854878
44.

Infections in children. Proceedings of the 4th Liverpool School of Tropical Medicine and Bayer Symposium on Microbial Disease.

Hart CA, Smyth RL, Duerden BI.

J Med Microbiol. 1998 Nov;47(11):943-82. Review. No abstract available.

PMID:
9822295
45.
46.

Typing of environmental Clostridium difficile strains.

al-Saif NM, Brazier JS, O'Neill G, Magee JT, Duerden BI.

Clin Infect Dis. 1997 Sep;25 Suppl 2:S202-3. No abstract available.

PMID:
9310678
47.

Zoonoses. Introduction.

Hart CA, Trees AJ, Duerden BI.

J Med Microbiol. 1997 Jan;46(1):4-6. Review. No abstract available.

PMID:
9003735
48.

The occurrence of bacteraemia with skin surgery.

Carmichael AJ, Flanagan PG, Holt PJ, Duerden BI.

Br J Dermatol. 1996 Jan;134(1):120-2.

PMID:
8745896
49.

Effects of surgical treatment on the microbial flora in residual periodontal pockets.

Rawlinson A, Duerden BI, Goodwin L.

Eur J Prosthodont Restor Dent. 1995 Jun;3(4):155-61.

PMID:
8601158
50.

Correlation of pyrolysis mass spectrometry and outer membrane protein profiles of Clostridium difficile.

Ogunsola FT, Magee JT, Duerden BI.

Clin Infect Dis. 1995 Jun;20 Suppl 2:S331-3. No abstract available.

PMID:
7548589

Supplemental Content

Loading ...
Support Center